




17-AAG  
Observed DR,  $r = 0.507$ ,  $n = 297$




Tanespimycin  
GDSC,  $r = 0.644$ ,  $n = 529$




17-AAG  
CCLE,  $r = 0.535$ ,  $n = 454$




Tanespimycin  
Predicted DR,  $r = 0.325$ ,  $n = 297$




AZD0530  
Observed DR,  $r = 0.557$ ,  $n = 105$




Saracatinib  
GDSC,  $r = 0.484$ ,  $n = 236$




AZD0530  
CCLE,  $r = 0.515$ ,  $n = 455$




Saracatinib  
Predicted DR,  $r = 0.637$ ,  $n = 105$




Erlotinib  
Observed DR,  $r = 0.366$ ,  $n = 92$




Erlotinib  
GDSC,  $r = 0.521$ ,  $n = 207$




Erlotinib  
CCLE,  $r = 0.515$ ,  $n = 454$




Erlotinib  
Predicted DR,  $r = 0.674$ ,  $n = 92$




Lapatinib  
Observed DR,  $r = 0.492$ ,  $n = 98$




Lapatinib  
GDSC,  $r = 0.664$ ,  $n = 225$




Lapatinib  
CCLE,  $r = 0.608$ ,  $n = 455$




Lapatinib  
Predicted DR,  $r = 0.577$ ,  $n = 98$




Nilotinib  
Observed DR,  $r = 0.75$ ,  $n = 228$




Nilotinib  
GDSC,  $r = 0.691$ ,  $n = 509$




Nilotinib  
CCLE,  $r = 0.561$ ,  $n = 375$




Nilotinib  
Predicted DR,  $r = 0.83$ ,  $n = 228$




Nutlin-3  
Observed DR,  $r = 0.277$ ,  $n = 298$




Nutlin-3a (-)  
GDSC,  $r = 0.61$ ,  $n = 529$



Nutlin-3  
CCLE,  $r = 0.414$ ,  $n = 455$




Nutlin-3a (-)  
Predicted DR,  $r = 0.61$ ,  $n = 298$







Paclitaxel  
Observed DR,  $r = 0.404$ ,  $n = 101$




Paclitaxel  
GDSC,  $r = 0.517$ ,  $n = 231$




Paclitaxel  
CCLE,  $r = 0.668$ ,  $n = 454$




Paclitaxel  
Predicted DR,  $r = 0.342$ ,  $n = 101$




PD-0325901  
Observed DR,  $r = 0.636$ ,  $n = 294$




PD0325901  
GDSC,  $r = 0.647$ ,  $n = 524$



PD-0325901  
CCLE,  $r = 0.734$ ,  $n = 455$




PD0325901  
Predicted DR,  $r = 0.826$ ,  $n = 294$







PD-0332991  
Observed DR,  $r = 0.174$ ,  $n = 240$




Palbociclib  
GDSC,  $r = 0.582$ ,  $n = 512$




PD-0332991  
CCLE,  $r = 0.573$ ,  $n = 388$




Palbociclib  
Predicted DR,  $r = 0.296$ ,  $n = 240$




PF-2341066  
Observed DR,  $r = 0.54$ ,  $n = 105$




Crizotinib  
GDSC,  $r = 0.594$ ,  $n = 235$




PF2341066  
CCLE,  $r = 0.526$ ,  $n = 455$




Crizotinib  
Predicted DR,  $r = 0.837$ ,  $n = 105$




PHA-665752  
Observed DR,  $r = 0.322$ ,  $n = 105$




PHA-665752  
GDSC,  $r = 0.551$ ,  $n = 236$




PHA-665752  
CCLE,  $r = 0.4$ ,  $n = 454$




PHA-665752  
Predicted DR,  $r = 0.725$ ,  $n = 105$




PLX4720  
Observed DR,  $r = 0.521$ ,  $n = 336$




PLX-4720  
GDSC,  $r = 0.669$ ,  $n = 604$




PLX4720  
CCLE,  $r = 0.575$ ,  $n = 447$




PLX-4720  
Predicted DR,  $r = 0.796$ ,  $n = 336$




Sorafenib  
Observed DR,  $r = 0.401$ ,  $n = 101$




Sorafenib  
GDSC,  $r = 0.45$ ,  $n = 229$




Sorafenib  
CCLE,  $r = 0.542$ ,  $n = 454$




Sorafenib  
Predicted DR,  $r = 0.828$ ,  $n = 101$




TAE684  
Observed DR,  $r = 0.486$ ,  $n = 105$



NVP-TAE684  
GDSC,  $r = 0.618$ ,  $n = 235$



TAE684  
CCLE,  $r = 0.607$ ,  $n = 455$



NVP-TAE684  
Predicted DR,  $r = 0.719$ ,  $n = 105$

